Clinical trials: pills and oral medicines
Adrenal Insufficiency
An Investigational Study of Hydrocortisone
This study will investigate a new drug called Infacort®; a newly-developed immediate release formulation of a well-established drug called hydrocortisone.
- Trial name
- NCT01960530
- Testing
- Hydrocortisone granules, Hydrocortisone Tablet, i.v. Hydrocortisone Injection
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Neurocrine UK Limited
HIV Infections
A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories
The purpose of the study is to evaluate the appropriateness, adoption, feasibility, fidelity, and acceptability of implementation strategies and Cabotegravir (CAB) pre-exposure prophylaxis (PrEP).
- Trial name
- EBONI (NCT05514509)
- Testing
- APRETUDE, Cabotegravir tablet
- Where
- 22 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV-1-infection
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen for 14 days (functional monotherapy) in people with human immunodeficiency…
- Trial name
- CAPELLA (NCT04150068)
- Testing
- Oral Lenacapavir, Subcutaneous Lenacapavir, Failing ARV Regimen
- Where
- 75 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Gilead Sciences
Hyperinsulinemia, Insulin Resistance
Glycemic Effect of Diazoxide in NAFLD
The goal of this clinical trial is to compare a two-week course of diazoxide (at two different doses) and placebo in people with overweight/obesity and insulin resistance (IR) with, or at high risk for, non-alcoholic fatty liver…
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
- Trial name
- NCT05729282
- Testing
- Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, FreeStyle Libre Pro
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Columbia University
Healthy Volunteers
A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Hydroxycarbamide in Healthy Volunteers
This study is a Phase I, open-label, single-centre, randomised, two-period, single-dose crossover study to compare and assess the bioequivalence, safety, tolerability and pharmacokinetics of hydroxycarbamide dispersible tablets…
- Trial name
- NCT05025072
- Testing
- Hydroxycarbamide dispersible tablets, Hydroxycarbamide film-coated tablet
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Theravia
Rheumatoid Arthritis
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.
- Trial name
- NCT05279417
- Testing
- ATI-450 50 mg oral tablet BID, Methotrexate, ATI-450 20 mg oral tablet BID
- Where
- 50 sites in United States, Bulgaria and 2 more
- Volunteers
- 251 people
- Sponsor
- Aclaris Therapeutics, Inc.
Liver Cirrhosis
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and…
- Trial name
- ZEAL (NCT05516498)
- Testing
- Part A: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin
- Where
- 50 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- AstraZeneca
Pancreatitis, Acute
Safety and Tolerability of Pirfenidone in Acute Pancreatitis
The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis.
- Trial name
- NCT05350371
- Testing
- Pirfenidone Oral Tablet
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Peanut Allergy, Multi-food Allergy
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew…
- Trial name
- OUtMATCH (NCT03881696)
- Testing
- Omalizumab, Multi-Allergen Oral Immunotherapy
- Where
- 10 sites in United States
- Volunteers
- 458 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
The purpose of this study was to compare the efficacy, safety, and durability of two different strategies to treat participants with a history of sub-optimal adherence and control of their HIV infection: long-acting (LA)…
- Trial name
- NCT03635788
- Testing
- Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB
- Where
- 33 sites in United States, Puerto Rico
- Volunteers
- 456 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants
The purpose of this study is to assess the relative bioavailability (BA) of 300 milligram (mg) TAK-935 tablets compared to 300 mg of TAK-935 solution and to determine the effect of food on the BA of TAK-935 300 mg tablets in…
- Trial name
- NCT02906813
- Testing
- TAK-935 Tablets, TAK-935 Oral Solution
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Volunteers
Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants
The purpose of this study is to determine absolute bioavailability (ABA) of TAK-935 (F) following a single microdose intravenous (IV) administration of 50 microgram (μg) (approximately 1 microcurie [μCi]) [14C]TAK-935 and a…
- Trial name
- NCT04992442
- Testing
- TAK-935 Oral Tablet, [14C]TAK-935 IV Infusion, [14C]TAK-935 Oral Solution
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Takeda
Smallpox
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
An open-label, drug-drug interaction study with TPOXX and phosphate binders.
- Trial name
- NCT04485039
- Testing
- Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- SIGA Technologies
Acute Heart Failure, Diuretics Drug Reactions
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment
This is a pragmatic, multicenter, interventional, parallel-arm, randomized, open-label trial to investigate whether a diuretic regimen, based on serial assessment of sodium concentration (UNa) on spot urine samples after diuretic…
- Trial name
- DECONGEST (NCT05411991)
- Testing
- UNa measurement after intravenous loop diuretic bolus, Intravenous acetazolamide 500 mg OD, Intravenous bumetanide TID
- Where
- 2 sites in Belgium
- Volunteers
- 107 people
- Sponsor
- Vrije Universiteit Brussel
HIV Infections
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
Dolutegravir (DTG) plus lamivudine (3TC) is a dual regimen combination recommended for both naïve and suppressed persons with HIV-1 infection1.
- Trial name
- VOLVER (NCT04880785)
- Testing
- Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]
- Where
- 17 sites in Spain
- Volunteers
- 167 people
- Sponsor
- Fundacion SEIMC-GESIDA
Ligament Injury
Do Oral Contraceptives Protect Against ACL Injuries in Female Athletes
The purpose of this research study is to examine the impact of one type of commonly used birth control pill on blood levels of relaxin and measure changes in knee movement to determine whether there are changes in joint…
- Trial name
- OC (NCT04899778)
- Testing
- Oral Contraceptive Pill, norethindrn a-e estradiol-iron
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1
The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Myotonic Dystrophy Type 1 ages 18 to 65 years.
- Trial name
- NCT04886518
- Testing
- Pitolisant Oral Tablet
- Where
- 13 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Harmony Biosciences Management, Inc.
Male Osteoporosis
Novel Combination Therapy for Osteoporosis in Men
Osteoporotic fractures are a key health problem in older men. Although there are drugs approved to treat osteoporosis in men [bisphosphonates, denosumab, and teriparatide (TPTD) or PTH(1-34)], there is a lack of knowledge on how…
- Trial name
- Osteo-Men (NCT03994172)
- Testing
- Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, Calcium citrate tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Friedreich Ataxia
A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia
In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®. The main goal of this study is to learn more about the safety of RTA 408 and how it affects physical effort…
- Trial name
- NCT02255435
- Testing
- Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg
- Where
- 11 sites in United States, Australia and 3 more
- Volunteers
- 172 people
- Sponsor
- Biogen
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic…
- Trial name
- NCT04246177
- Testing
- Lenvatinib, Pembrolizumab, TACE
- Where
- 205 sites in United States, Australia and 25 more
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC